Investigational^↗Metabolic^↗

Maridebart cafraglutide^↗

Related names in cited records: MariTide, AMG 133^↗

An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.^↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. ¹

This version supersedes public version 1.

Evidence summary

What the cited records say

ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.^↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Dated source history

July 21, 2026
Clinical trials
MariTide bioavailability study record updated^↗
ClinicalTrials.gov lists a completed Maridebart cafraglutide study sponsored by Amgen.^↗